4DMT Provides Company Update and Anticipated Development Milestones for 2026

Core Insights - 4D Molecular Therapeutics (4DMT) is advancing its lead product candidate, 4D-150, aimed at treating retinal vascular diseases, with significant milestones expected in 2026 [1][14] Leadership Changes - Glenn P. Sblendorio has joined the Board of Directors, bringing extensive experience from IVERIC Bio and The Medicines Company, which will support the company's late-stage execution and commercial readiness [3][7] - Katy Barglow, Ph.D., has been promoted to Chief Technical Officer, overseeing the transition to commercial manufacturing [12] - Kim Maplestone has been promoted to Chief Clinical Operations Officer, responsible for global clinical operations [12] - Chris Simms' role has expanded to Chief Commercial & Business Officer, including business development oversight [12] - Fred Kamal, Ph.D., has transitioned to Chief Technical Advisor, supporting CMC and regulatory strategy for 4D-150 [12] Clinical Development Updates - Enrollment in the 4D-150 Phase 3 wet AMD clinical trials is exceeding expectations, with 381 patients randomized or approved to randomize as of January 6, 2026, and completion expected in Q1 2026 [4][5] - The target enrollment for the 4FRONT Global Phase 3 Program has increased from 400 to 480 patients per trial, providing approximately 90% power for regulatory success [5] - Topline data from the 4FRONT-1 trial is expected in H1 2027, while the 4FRONT-2 trial is on track for completion in H2 2026 [5] - 4D-150's Phase 2b data from the PRISM trial is expected to be presented in mid-2026 [4][5] Financial Position - As of December 31, 2025, the company reported $514 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028 [9] Upcoming Events - The company will present its strategic outlook at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 a.m. PT [10]